Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of tepotinib plus cetuximab in metastatic colorectal cancer
2020-001776-15Phase 2Unknown
- Sponsor
- Merck KGaA
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tepotinib in metastatic colorectal adenocarcinoma (mCRC), sponsored by Merck KGaA. Primary endpoints: Safety and tolerability in safety run-in and Overall study primary endpoint. Status: unknown.
02
Drugs
tepotinib
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2020-001776-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001776-15.